Wells Fargo lowered the firm’s price target on Repligen (RGEN) to $180 from $190 and keeps an Overweight rating on the shares. The firm notes the company post a solid top- and bottom-line beat. 2026 guide bracketed consensus on core revenue and operating profit, while EPS missed on below-the-line items. The guide embeds conservatism on macro, but Wells thinks leaves room for upside, especially given strong Q1 start.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target lowered to $175 from $200 at Barclays
- Repligen Signals Confident Growth Path In 2026 Outlook
- Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating
- Repligen reports Q4 adjusted EPS 49c, consensus 44c
- Repligen sees FY26 EPS $1.93-$2.01, consensus $2.07